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Aims Although atrial fibrillation (AF) is increasingly common in developed countries, there is limited information regard-
ing its demographics, co-morbidities, treatments and outcomes in the developing countries. We present the profile
of the TuRkish Atrial Fibrillation (TRAF) cohort which provides real-life data about prevalence, incidence, co-




The TRAF cohort was extracted from MEDULA, a health insurance database linking hospitals, general practitioners,
pharmacies and outpatient clinics for almost 100% of the inhabitants of the country. The cohort includes 507 136
individuals with AF between 2008 and 2012 aged >18 years who survived the first 30 days following diagnosis. Of
507 136 subjects, there were 423 109 (83.4%) with non-valvular AF and 84 027 (16.6%) with valvular AF. The
prevalence was 0.80% in non-valvular AF and 0.28% in valvular AF; in 2012 the incidence of non-valvular AF
(0.17%) was higher than valvular AF (0.04%). All-cause mortality was 19.19% (97 368) and 11.47% (58 161) at 1-
year after diagnosis of AF. There were 35 707 (7.04%) ischaemic stroke/TIA/thromboembolism at baseline and 34
871 (6.87%) during follow-up; 11 472 (2.26%) major haemorrhages at baseline and 10 183 (2.01%) during follow-
up, and 44 116 (8.69%) hospitalizations during the follow-up.
...................................................................................................................................................................................................
Conclusion The TRAF cohort is the first population-based, whole-country cohort of AF epidemiology, quality of care and out-
comes. It provides a unique opportunity to study the patterns, causes and impact of treatments on the incidence
and outcomes of AF in a developing country.
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Introduction
Atrial fibrillation (AF) is the most common sustained clinical arrhyth-
mia. It conveys a substantial international health and wealth burden,
which is mostly driven by high rates of stroke, thromboembolism and
death1. Moreover, the prevalence and incidence of AF is increasing,
especially in the developed countries with an increase in the elderly
population2. Although the epidemiology of AF has been extensively
reported in modern healthcare systems, there are no qualified data
about the demographics, risk factors, treatments and outcomes
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among developing countries. Typically, these countries have younger
populations and rapidly embrace new health technologies. In add-
ition, most of the randomized data that are used to report the epi-
demiological features of AF, to date, only included a limited number
of patients living in finite areas. There are no population-based or
whole-country studies of the life course of patients with AF from
aetiology to treatment to healthcare utilization, morbidity and death.
We have established the first whole-country cohort of individual
patient data from a systematic health insurance database which cov-
ers nearly all 50 364 653 inhabitants over the age of 18 in the country.
The overall aim of the TuRkish Atrial Fibrillation (TRAF) cohort is to
provide real life data about the prevalence, incidence, demographics,
co-morbidities, treatments, quality of care and outcomes for all types
of AF. Here in, we present the overall design and methods of the
TRAF cohort, the age- and sex-specific prevalence and incidence of
AF, as well as data for prescribed drugs, co-morbidities and observed




Data for the TRAF cohort were obtained from the Turkish claims and
utilization management system, MEDULA, which processes claims for all
health insurance funds in Turkey. Covering close to 100% of the popula-
tion, MEDULA is comprised of pharmacy, inpatient, outpatient and la-
boratory claims and across 23 500 pharmacies, 20 000 general
practitioners, 850 government hospitals, 60 university hospitals and 500
private hospitals. Medical data entered into the MEDULA database by
physicians include patient demographics, prescription details, observed
clinical events, outpatient clinics, inpatient hospitalizations and major clin-
ical outcomes. For each hospitalization, the dates of admission and dis-
charge, main diagnoses and major outcomes are recorded. The MEDULA
system links to the Turkish national death database, whereby information
concerning date and cause of death are available. The TRAF cohort is
formed from extracted anonymized patient-level data.
Study population
We included all individuals with a diagnosis of AF who were aged over 18
years between 1 January 2008 and 31 December 2012 and who survived
the first 30 days following their diagnosis of AF. We excluded those pa-
tients who died very early after a diagnosis of AF presumably because
their death would be unlikely to be associated with AF. We used ICD-10
code I48 to identify AF. We defined patients as having non-valvular AF ac-
cording to international guidelines by excluding those who had mitral
stenosis (I342, I050 and Q232) or a history of valve surgery (Z95). We
defined lone AF as those patients with non-valvular AF who had no co-
morbidity.
Co-morbidity data
Co-morbidity data such as hypertension (I10–15), heart failure (I50),
chronic obstructive airways disease, COPD (J43-44), peripheral vascular
disease (I70–73), diabetes mellitus (E10-14) and acute myocardial infarc-
tion (I21, I25.2), hyperthyroidism (E05), renal disease (N17-19), and out-
comes data including thromboembolic (ischaemic stroke (I63), non-
specified stroke (I64), transient ischaemic attack, TIA (G45) systemic
emboli (I74)) and major haemorrhagic (haemorrhagic stroke (I62.9),
others) events were extracted. The ICD-10 codes used for the diagnostic
categories can be seen in Table 1.
Prescribed medications data
We used the ATC/DDD Index of drug codes to identify prescribed medi-
cations.4 Extracted medications data included that for warfarin
(B01AA03), acetyl salicylic acid (aspirin) (B01AC06), clopidogrel
(B01AC04), b blockers (C07), verapamil (C08DA01), diltiazem
(C08DB01), amiodarone (C01BD01), sotalol (C07AA07) and propafe-
none (C01BC03). During the study period, warfarin was the only oral
anticoagulant available for AF.
Healthcare utilization and outcomes data
We extracted from the MEDULA database dates of hospital admissions
and discharges along with the reason for hospitalization.
Stroke risk schemes
We extracted patient-level information to enable the calculation of
CHA2DS2Vasc stoke risk schemes for AF. Components of the
CHA2DS2Vasc score were defined by a diagnosis of heart failure, hyper-
tension, age at inclusion, diabetes mellitus and previous ischemic stroke,
unspecified stroke, TIA, or systemic emboli, vascular disease (prior acute
myocardial infarction, peripheral arterial disease) and sex category.3
Using ICD-10 codes alone, heart failure, coronary artery disease, dia-
betes, hypertension and stroke can be ruled in but not necessarily ruled
out. We used some review of additional data (e.g. physician notes or
imaging studies) to confirm the diagnosis of valvular disease, arterial per-
ipheral embolus, intracranial haemorrhage and deep venous thrombosis.5
Statistical analysis
The distribution of continuous variables was determined using the
Kolmogorov–Smirnov test. Continuous variables with normal distribu-
tion were expressed as means± standard deviations (SD). Variables with
skew distributions were expressed as median (minimum–maximum) and
categorical variables expressed as proportions.
Categorical variables were compared using the v2-squared test, nor-
mally distributed numeric variables compared using the independent sam-
ples Students t test, and skewed numeric variables compared using the
Mann–Whitney U test. Pearson or Spearman’s correlation, where appro-
priate, was used to explore the associations between study parameters.
Age- and sex-standardized rates of the incidence of AF were calculated.
Generalized ordinal logistic regression models were used to quantify the
impact of independent risk factors for AF. Two-sided values of P < 0.05
were considered statistically significant. All analyses were performed
using SPSS 15.0, R and STATA 8.0 software.
What’s new?
• In this cohort, a whole country data of atrial fibrillation epi-
demiology is presented.
• This study reported the causes and impact of treatments on
the incidence and outcomes of AF in a developing country.
• This cohort demonstrated that low incidence of AF, higher fre-
quency in women and inappropriate/inadequate use of oral
anticoagulants in a developing country.
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Results
Between 2008 and 2012, the estimated prevalence of AF in the coun-
try was 1.08%. Figure 1 shows Gender distribution segmented with
the incidence years for all AF patients. Age distribution of AF is dem-
onstrated in Figure 2.
Of 507 136 subjects between 2008 and 2012, aged over 18 years
who had a diagnosis of AF and survived the first 30 days after index
date, there were 423 109 (83.4%) with non-valvular AF and 84 027
(16.6%) with valvular AF. Of those with non-valvular AF, 30 651 (7.24%)
had lone AF. Overall, there were 2 360 191.75 person-years of
follow-up over a mean of 55.85 (±0.0304) months. For this cohort, the
mean age was 66.04 (±0.02) years, 57.14% were female. All-cause
mortality was 19.19% (97 368) and 11.47% (58 161) all-cause mortal-
ity at 1-year after diagnosis of AF. There were 35 707 (7.04%) ischae-
mic stroke/TIA/thromboembolism at baseline and 34 871 (6.87%)
during follow-up, 11 472 (2.26%) major haemorrhages at baseline
and 10 183 (2.01%) during follow-up, and 44 116 (8.69%) hospitaliza-
tions during follow-up. The median (min-max) CHA2DS2Vasc score
was 4 (0–9).
Non-valvular AF
For individuals with non-valvular AF, the mean age was 66.11 (±0.02)
years, 55.92% were female. The prevalence was 0.80% and the inci-
dence was 0.17% in 2012. The prevalence of non-valvular AF
increased with increasing age. Figure 3 shows the prevalence of non-
valvular AF by age.
Among this group, the frequencies of baseline co-morbidities were
hypertension 84.87%, heart failure 54.89%, COPD 31.94%, diabetes
mellitus 19.74% and acute myocardial infarction 7.35% (Figure 4).
One-year hospitalization rate following the diagnosis was 3.22% (13
612). A total of 27 909 (6.59%) patients had an ischemic stroke/TIA/
thromboembolism after their diagnosis of non-valvular AF. The yearly
rate of stroke/TE according to CHA2DS2Vasc score is shown in
Figure 5. All-cause mortality at 1-year after diagnosis of non-valvular
AF was 12.07% (51 068 individuals). Number and % of patients in
each CHA2DS2Vasc score is given at Table 2.
Valvular AF
For subjects with valvular AF mean age was 65.68 (±0.045) years,
63.29% were female. The prevalence was 0.28%, the incidence was
0.04% in 2012. The prevalence of valvular AF also increased by age;
being 0.01% for ages 19–29 years, 0.04% for ages 30–39 years, 0.14%
for ages 40–49 years, 0.38% for ages 50–59 years, 0.84% for ages 60–
69 years, 1.44% for ages 70–79 years, 1.22% for ages 80–89 years and
0.73% over the age of 90 years (Figure 6 shows the age distribution of
valvular AF prevalence).
Major baseline co-morbidities for this group included hypertension
(79.20%), heart failure (42.64%), COPD (29.64%), diabetes mellitus
(20.49%), and acute myocardial infarction (7.96%) of the patients
with valvular AF (Figure 7). One-year hospitalization rate after diagno-
sis of valvular AF was 5.58%. A total of 6962 patients (8.28%) had an
ischemic stroke/TIA/thromboembolism after their diagnoses of
valvular AF. All-cause mortality rate for the 5-years following the
diagnosis of valvular AF was 17.7% (14 929 individuals).
Lone AF
Individuals without any comorbidity constituted the 7.24% (30 651)
of the group with non-valvular AF. When we considered individuals
with lone AF aged less than 60 years, the frequency was 4.93% (20
891).
However, all-cause mortality rate for the 5-year follow-up was
7.77% (2382) across all ages and 1.78% (372) among those under 60
years of age.
Discussion
Atrial fibrillation is a heterogeneous condition with significant differ-
ences in its epidemiology, pathogenesis, clinical presentation and
management across the age groups. Most of the published data re-
garding the epidemiology and prognosis of atrial fibrillation arise from
Northern America and the Western European countries. There are
no total cohort studies of AF. Our population-based cohort of AF is
the first-of-its-kind, as well as being unique because it comprises data
from a developing country.
Data from the TRAF cohort suggest that the prevalence and the
incidence of non-valvular AF in Turkey is lower than that reported in
Western healthcare systems. In the UK between 2009 and 2012, for
example, an analysis of 13.1 million patients in primary care revealed
a prevalence of AF of 1.76%.6–8 Our lower rate probably reflects the
younger demographics of the Turkish population in concert, and a
.................................................................................................
Table 1 ICD-10 codes and frequencies
Diagnosis ICD-10 code Frequency (%)
Heart failure I50 226 545 (44.67)
Hypertension I10-15 406 358 (80.13)
Diabetes mellitus E10-14 103 305 (20.37)
Haemorrhagic stroke I62.9 672 (0.13)
Ischemic stroke I63 26 876 (5.30)
Stroke, unspecified I64 5195 (1.02)




Thromboembolic event I63-64, G45, I74 35 707 (7.04)
Acute myocardial
infarction
I21, I252 39 852 (7.86)
Ischemic heart disease I20–25 347 241 (68.47)
Peripheral arterial disease I70–73 35 524 (7.01)
Vascular disease I21, I252, I65, I70-73 70 560 (13.91)
Valvular disease I05-09, I33-39 84 027 (16.57)
Mitral stenosis I342, I050, I052, Q232 17 647 (3.48)






J40-70 152 278 (30.03)
Emphysema/COPD J43-44 152 278 (30.03)
Hyperthyroidism E05 34 726 (6.85)
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well-recognized strongly positive association with increasing age. In
Turkey, the median age is 30.1 years and only 7.5% of inhabitants of
Turkey are over 65 years of age.9 This compares with a median age of
37.2 and 38.0 years and 13.3% and 16.7% over the ages of 65 years in
Northern America and Europe, respectively.10,11
Although the prevalence of non-valvular AF was lower than that
reported in the Western world, we found a higher prevalence of
valvular AF in Turkey. Acute rheumatic fever and its complications,
although significantly reduced, have not been eradicated yet. This is
an important finding from our study which has critical public health
repercussion should Turkey wish to address preventable valvular
heart disease and associated valvular AF. Notwithstanding this, the
current figure of more than half a million patients with AF will result
in a significant and increasing burden on health economy of the coun-
try. This burden will be driven by an aging and multi-morbid popula-
tion in coming years.
In the previous reports from the Western healthcare systems,
the prevalence of AF has been reported to be greater in men than
women.1 In the TRAF cohort, in contrast to the ATRIA study,
Euro Heart Survey and Framingham study we found a higher fre-
quency of non-valvular AF in women.12–14 Although we do not
have a clear explanation it might be related to the high prevalence
of obesity, metabolic syndrome and cardiovascular diseases in
Turkish women over the age of 40 as compared to the European
Countries.15
Another important finding from the TRAF cohort was contempor-
ary and population-based evidence for high mortality rates among pa-
tients with AF that occurred early following index diagnosis. In the
literature, AF is reported to confer a 5-fold risk of stroke and 2-fold
risk of mortality.1,16 We found that the rate of death at 1 year was
7.04%.
The increasing incidence and prevalence of AF will continue to
impose a considerable burden on the Turkish medical health-care
system.17–19 While we found a well-reported association among
AF, increasing age and concomitant diseases such as hypertension,
coronary artery disease, and heart failure,20–22 data from the
TRAF cohort will help determine whether the excess mortality
observed in patients with AF is directly due to AF or is just an as-
sociation. That is, other large cohort-based studies have shown
AF to be independent predictor of increased late mortality.23
Data from the Framingham study revealed a 1.5- to 1.9-fold risk of
mortality in patients with AF in both gender across a wide range of
ages even after adjustment for pre-existing cardiovascular dis-
ease.24 In another study, Wolf et al.25 found that the adjusted rela-
tive risk of mortality was about 20% higher in patients with AF
during 3 years of follow-up. There was no significant difference be-
tween age categories or genders during follow-up. In another
study, Frost et al.26 found a statistically significant difference in the
relative risk of mortality between genders in age categories older
than 70 years during 14 years of follow-up. Andersson et al.19 re-
ported an adjusted relative risk for all-cause mortality among pa-
tients with an incident AF of 1.5–2, with higher relative risks in
younger individuals and females.
The costs associated with AF patient care are high and are driven
largely by the cost of hospitalization. A number of real-world obser-
vational studies have demonstrated that patients with AF are fre-
quently admitted or readmitted to hospital. In a study reported by
Naccarelli et al.,27 more than half (51.9%) were hospitalized with non-
fatal outcomes over a mean follow-up period of 24 months and
38.3% were hospitalized during the first year. Wu et al.28–30 reported
nearly half of the patients with AF required one inpatient visit over 1
year compared with 6.6% of a matched non-AF sample. In the study
of Naccarelli et al.,27 27.2% of patients were hospitalized for CV
causes over the 2 years of follow-up. In our study, 31.5% of all pa-
tients with AF were hospitalized during follow-up period.
Potential limitations of this study should be addressed. The lower
prevalence and incidence of AF in this study might be related to non-
optimal screening for AF. This is a database study and some AF pa-
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Figure 1 Gender distribution segmented with the incidence
years for all AF patients (N = 507 136) (A), for non-valvular AF
patients (N = 423 109) (B) and for valvular AF patients (N = 84 027)
(C).
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Conclusion
The TRAF cohort provides real-life data in a whole country cohort of
AF. It contains detailed information about incidence, prevalence,
co-morbidities, treatments and outcomes. The difference in epidemi-
ology in a developing country has been highlighted. The unique fea-
tures included low incidence of AF, higher frequency in women. The
increasing burden on the healthcare system with the ageing of the
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Figure 4 Baseline comorbidities in non-valvular AF patients.
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Figure 7 Comorbidities in valvular AF.
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